PharmaFocus Today – Page 15 – media

Haobo Medical ASO treats hepatitis B, with a negative conversion rate of over 60%

Hepatitis B, as one of the common infectious diseases worldwide, has long troubled the medical community and patients. Although a variety of treatments are available, achieving functional cure of hepatitis B has always been the focus and difficulty of medical research. Recently, according to a report by “Liver Time”, Haobo Pharmaceutical has made breakthrough progress in the treatment of hepatitis B through its independently developed ASO therapy AHB-137. Clinical trial data shows that the HBsAg negative conversion rate of AHB-137 exceeds 60%. It provides new hope for the treatment of hepatitis B. AHB-137 is carefully developed by Haobo Pharmaceutical through its unique scientific research platform Med-Oligo™. This ASO (antisense oligonucleotide) drug has shown remarkable results in clinical trials for the treatment of hepatitis B. According to public data, among patients with baseline HBsAg levels of 100-3000IU/ml, after 12 weeks of treatment, 62% and 43% of patients in the 300 mg ...
- Source: drugdu
- 82
- November 26, 2024
Overly worried about the “scissors gap” of medical insurance revenue and expenditure

Regarding the problem of the “scissors gap” of medical insurance, we need to worry, but we also need to have confidence in solving it. Although the long-term pressure on medical insurance funds is increasing under the severe situation of population aging, ten years ago, there were still three employees supporting one retired employee. Last year, the ratio of employees’ basic medical insurance to retired employees dropped to 2.71. In the long run, there may be fewer and fewer people paying money, and more and more people spending money, and the medical expenses of the elderly will increase with age. This “scissors gap” will undoubtedly bring huge pressure to the sustainability of medical insurance financing and operation. However, there are always more solutions than difficulties. Referring to Japan, where the aging population is more serious, in addition to drastic price control reforms, Japan has promoted the operation of the national health ...
- Source: drugdu
- 53
- November 26, 2024
BeiGene’s Category 1 innovative cancer drug has been approved for clinical trials! New target for “synthetic lethality”

On November 19, the official website of the Center for Drug Evaluation (CDE) of the China State Food and Drug Administration announced that BGB-58067, a Class 1 new drug submitted by BeiGene, has received implicit approval for clinical trials and is planned to be developed to treat patients with advanced solid tumors. According to BeiGene’s public information, BGB-58067 is a PRMT5 inhibitor and one of BeiGene’s future core projects. According to the CDE official website, this is the first time this product has been approved for clinical use in China. PRMT5 is a new target in the field of “synthetic lethality”. Research has found that the gene that constitutes “synthetic lethality” with PRMT5 is MTAP, which is a tumor suppressor gene that is often deleted in tumors. Loss of MTAP will cause the accumulation of its reaction substrate methylthioadenosine (MTA), and MTA will combine with PRMT5 to form a PRMT5-MTA ...
- Source: drugdu
- 66
- November 26, 2024
Nearly 97% of patients reached lipoprotein standards within 3 months! Eli Lilly announces impressive results for oral inhibitor

Eli Lilly and Company recently announced that its investigational once-daily oral lipoprotein(a)-Lp(a) inhibitor muvalaplin achieved positive results in a Phase 2 clinical trial. The study showed that the trial met the primary endpoint. Muvalaplin could significantly reduce elevated Lp(a) levels in adult patients, and the patients’ percentage change in Lp(a) levels from baseline to week 12 showed significant improvement. These data were published in the journal JAMA and released simultaneously at the 2024 American Heart Association (AHA) Annual Scientific Meeting. Muvalaplin is an orally administered small molecule that inhibits Lp(a) formation by blocking the apo(a)-apo B100 interaction while avoiding the interaction with the homologous protein plasminogen. The analysis showed that muvalaplin (10 mg, 60 mg and 240 mg) significantly reduced patients’ Lp(a) levels in the primary endpoint at week 12. Placebo-adjusted Lp(a) reductions were up to 85.8% as assessed by the intact Lp(a) assay and up to 70.0% as assessed ...
- Source: drugdu
- 81
- November 26, 2024
16.5 billion big drug, the first domestic drug is about to be approved

Currently, there is only one Bcl-2 inhibitor in the world, venetoclax, which is jointly developed by AbbVie and Roche. AbbVie’s financial report shows that in 2023, venetoclax’s revenue will reach US$2.28 billion (approximately RMB 16.5 billion), a year-on-year increase of 13.9%. Such an attractive golden big single product, the first domestic drug is about to usher in a breakthrough. Recently, Ascent Pharmaceuticals announced that its independently developed new selective Bcl-2 inhibitor APG-2575’s new drug application (NDA) has been accepted by the CDE and recommended for inclusion in the priority review process for the treatment of refractory or relapsed (r/r) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This is the first domestic original Bcl-2 inhibitor to submit an NDA in China, and is expected to become the second Bcl-2 inhibitor to be listed in the world. 16.5 billion big drug, the first domestic product is accelerating to the finish line. The “strongest ...
- Source: drugdu
- 69
- November 25, 2024
Domestic molecules become king bombs overseas

Recently, BionTech chose to go a step further after completing the BD transaction of Promis bispecific antibody: it completely acquired Promis, a Chinese multi-antibody biotech. The day after the announcement of the acquisition, BioNTech held the 2024 R&D Day in full swing. Most of the report was devoted to describing the cancer treatment strategy centered on the bispecific antibody PM8002 developed by Promis, and clarified that the acquisition of PM8002 is a highlight in the company’s future strategic blueprint. From 2023, we can see that BioNTech is frequently sweeping up domestic pipelines. A total of four ADC pipelines from two high-quality biotechs, Yilian and Yingen, as well as PM8002 from Promis, were all acquired by BioNTech. From the timeline, BioNTech first conducted BD transactions for several ADC pipelines in 2023, and then completed the BD of Promis bispecific antibody at the end of 2023. From today’s perspective, BioNTech regards PM8002 ...
- Source: drugdu
- 73
- November 25, 2024
The next hot topic of HPV vaccine is here, let men get it too!

On November 18, Wantai Bio released an announcement stating that it has obtained approval from the National Medical Products Administration to conduct clinical trials for the indications of the nine-valent HPV vaccine for males. Wantai Bio pointed out that among the male population worldwide, about 70,000 new cancer cases are related to HPV infection each year, such as penile cancer, anal cancer, oropharyngeal cancer and other head and neck cancers. Of these cancers, about 90% can be attributed to polytypes of HPV6, 11, 16, 18, etc. Wantai Bio’s nine-valent HPV vaccine covers these viruses and can prevent precancerous lesions caused by these HPV viruses. With the saturation of the female market space, coupled with several rounds of internal competition for domestic HPV vaccines, even Merck’s nine-valent HPV vaccine has shown a decline this year. In the first half of 2024, Merck’s global sales of HPV vaccines increased by only 7% ...
- Source: drugdu
- 73
- November 25, 2024
World’s first! iPSC stem cell therapy restores human vision

On November 7, 2024, researchers from Osaka University published a research paper titled: Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan in the international top medical journal The Lancet. This clinical study is the first in the world to use corneal epithelial cell sheets (iCEPS) derived from human induced pluripotent stem cells (iPSCs) to repair the cornea of patients with limbal stem cell deficiency (LSCD) visual impairment. The results showed that this new regenerative therapy is safe and helped improve patients’ vision. The research team plans to conduct larger clinical trials to better understand the therapeutic effects of the therapy. In this study, ophthalmologist Kohji Nishida from Osaka University and his team used induced pluripotent stem cells (iPSCs) to treat limbal stem cell deficiency (LSCD). The research team extracted blood cells from a healthy donor, then reprogrammed them into iPSCs, which were ...
- Source: drugdu
- 63
- November 25, 2024
Baique Ling’s products involved have no violations, and the official flag’s daily sales have increased by 500%

On November 22nd, China Net Finance reported that in response to the recent widespread online rumors about the alleged addition of banned ingredients to cosmetics produced by Shanghai Baique Ling Daily Chemical Co., Ltd. (hereinafter referred to as “Baique Ling”), the Shanghai Food and Drug Administration issued the latest response on November 20th. After investigation, the Food and Drug Administration confirmed that there was no violation of the Regulations on the Supervision and Administration of Cosmetics and the regulations on the management of prohibited and restricted raw materials for the related product of lark, Shuinenjing essence facial cleanser (formula upgrade) (limited use date: 20241105, batch number: 3R06YV11). This conclusion has put an end to the controversy surrounding Baique Ling cosmetics. It is reported that the cause of the incident was that the Shanghai Food and Drug Administration received a report from netizens on September 27, saying that the ingredients on ...
- Source: drugdu
- 80
- November 23, 2024
750 million license in, Chinese pharmaceutical companies make money overseas and spend overseas

On November 20, Junshi Bio released an announcement and signed a License Agreement with an undisclosed licensor to obtain the exclusive license right and sub license right of the licensor to develop, manufacture, use, import, export, sell and commercialize the two dual target fusion proteins in Greater China (including Chinese Mainland, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan). The subject of this transaction is two dual target fusion proteins, mainly used for the treatment of malignant tumors. Currently, licensed product 1 is in the overseas Phase I clinical trial stage. Junshi Biotechnology has submitted its Phase I clinical trial application to the National Medical Products Administration in China, and Junshi Biotechnology has the right of first refusal for licensed product 1 outside of Greater China. Licensed product 2 is in the preclinical research stage. In addition to the exclusive license and sub license rights to develop, ...
- Source: drugdu
- 76
- November 23, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.